Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.